ArticleNeuropsychopharmacology reports2026
Prolonged Anti-Zic4 Antibody-Positive Cerebellar Degeneration Following COVID-19 Infection.
Article in Neuropsychopharmacology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prolonged Anti-Zic4 Antibody-Positive Cerebellar Degeneration Following COVID-19 Infection.Neuropsychopharmacology reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundAlthough anti-Zic4 antibodies are associated with paraneoplastic cerebellar degeneration, predominantly in small-cell lung carcinoma, their role in postinfectious autoimmunity remains poorly understood. CASE REPORT: Here, we report a 53-year-old woman who developed progressive cerebellar degeneration following coronavirus disease 2019 (COVID-19), characterized by isolated anti-Zic4 antibody positivity in the absence of malignancy. Two months after developing mild respiratory symptoms, she developed dysarthria, imbalance, and gait ataxia. Neurological examination revealed gaze-evoked nystagmus, broad-based ataxia, and cerebellar dysmetria. Brain MRI demonstrated marked cerebellar atrophy, while cerebrospinal fluid analysis showed elevated protein, increased IgG index, and the presence of oligoclonal bands. Serological testing confirmed strong anti-Zic4 antibody positivity. Initial treatment with intravenous immunoglobulin and plasmapheresis achieved transient improvement and decreased antibody titers. However, 1 year later, recurrence of antibodies coincided with further cerebellar atrophy and posterior hypoperfusion on MRI and SPECT, despite maintenance immunotherapy with low-dose corticosteroids and periodic IVIG. Cognitive function was well preserved, highlighting the selective vulnerability of cerebellar circuits.
conclusionThis case illustrates an unusual phenotype of prolonged, isolated anti-Zic4 antibody-associated cerebellar degeneration triggered by SARS-CoV-2 infection, thus expanding the recognized clinical spectrum of Zic4-related disorders beyond paraneoplastic contexts. The underlying immunopathological mechanisms have yet to be elucidated. Notably, radiological progression was disproportionate to clinical stabilization, underscoring the necessity of long-term clinical/imaging surveillance. This case highlights the need for further studies to clarify pathophysiological links between COVID-19 and persistent autoimmune cerebellar degeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.